Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group
| Autor: | Seufferlein, T., Uhl, W., Kornmann, M., Algül, H., Friess, H., König, A., Ghadimi, M., Gallmeier, E., Bartsch, D.K., Lutz, M.P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C.C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., Waldschmidt, D., Bruns, C., Wittel, U., Fichtner-Feigl, S., Daum, S., Hinke, A., Blome, L., Tannapfel, A., Kleger, A., Berger, A.W., Kestler, A.M.R., Schuhbaur, J.S., Perkhofer, L., Tempero, M., Reinacher-Schick, A.C., Ettrich, T.J. |
|---|---|
| Zdroj: | In Annals of Oncology January 2023 34(1):91-100 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|